Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT03134222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Lupus Erythematosus

Interventions

DRUG: Lanraplenib
DRUG: Filgotinib
DRUG: Lanraplenib placebo
DRUG: Filgotinib placebo

Sponsor

Gilead Sciences

Collaborators

[object Object]